Blanca Garcia-Micò

Blanca Garcia-Micò

Auto-generated profile, based on publicly available information

Blanca Garcia-Micò

Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2024 in Annals of Oncology
Verified
Journal Article
Open access
BMB. Martínez-Castedo
B. Martínez-Castedo
DGDaniel González-Camblor
Daniel González-Camblor
JMJ. Martín-Arana
J. Martín-Arana
JCJ.A. Carbonell-Asins
J.A. Carbonell-Asins
BGB. García-Micó
B. García-Micó
NTNoelia Tarazona
Noelia Tarazona
Circulating tumor DNA (ctDNA) analysis has emerged as a minimally invasive tool for detecting minimal residual disease (MRD) in colorectal cancer (CRC) patients. This enables dynamic risk stratification, earlier recurrence detection, and optimized post-surgical treatment. Two primary methodologies have been developed for ctDNA-based MRD detection: tumor-informed strategies, which identify tumor-specific mutations through initial tissue sequencing to guide ctDNA monitoring, and tumor-agnostic approaches, which utilize predefined panels to detect common cancer-associated genomic or epigenomic alterations directly from plasma without prior tissue analysis. The debate over which is superior in terms of sensitivity, specificity, cost-effectiveness, and clinical feasibility remains unresolved. This review summarizes studies published up to November 2024, exploring the utility and performance of tumor-informed and tumor-agnostic approaches for ctDNA analysis in CRC. We evaluate the strengths and limitations of each methodology, focusing on sensitivity, specificity, and clinical outcomes. Both strategies demonstrate clinical utility in postoperative risk stratification and guiding adjuvant chemotherapy decisions in CRC patients. Tumor-informed approaches generally exhibit superior sensitivity and specificity for recurrence prediction, attributed to their personalized tumor profile designs. However, these methods are limited by the need for prior tissue sequencing and higher associated costs. In contrast, tumor-agnostic approaches offer broader applicability due to their reliance on plasma-only analysis, although with relatively lower sensitivity. Technological advancements, including fragmentomics and multi-omic integrations, are expanding the capabilities of ctDNA-based MRD detection, enhancing the performance of both approaches. While tumor-informed strategies currently offer higher precision in MRD detection, tumor-agnostic approaches are gaining traction due to their convenience and improving performance metrics. The integration of novel technologies in ongoing clinical trials may redefine the optimal approach for MRD detection in CRC, paving the way for more personalized and adaptive patient management strategies.

29 April 2025 in Nature Cancer
Verified
Journal Article
Open access
PDF file
JMJorge Martín-Arana
Jorge Martín-Arana
FGFrancisco Gimeno-Valiente
Francisco Gimeno-Valiente
THTenna Vesterman Henriksen
Tenna Vesterman Henriksen
BGBlanca García-Micó
Blanca García-Micó
BMBelén Martínez-Castedo
Belén Martínez-Castedo
NTNoelia Tarazona
Noelia Tarazona
In stage 2–3 colon cancer (CC), postsurgery circulating tumor DNA (ctDNA) assessment is crucial for guiding adjuvant chemotherapy (ACT) decisions. While existing assays detect ctDNA and help identify high-risk persons with CC for recurrence, their limited sensitivity after surgery poses challenges in deciding on ACT. Additionally, a substantial portion of persons with CC fail to clear ctDNA after ACT, leading to recurrence. In this study, we performed whole-exome sequencing (WES) of ctDNA at different time points in participants with relapsed CC in two independent cohorts, alongside transcriptomic and proteomic analyses of metastases, to enhance comprehension of progression mechanisms. A plasma WES-based tumor-agnostic assay demonstrated higher sensitivity in detecting minimal residual disease (MRD) compared to current assays. Immune evasion appears to be the primary driver of progression in the localized CC setting, indicating the potential efficacy of immunotherapy for microsatellite stability in persons with CC. Organoid modeling further supports the promising potential of targeted therapy in eradicating MRD, surpassing conventional treatments.

9 November 2023 in ESMO Open
Verified
Journal Article
Open access
FGF. Gimeno-Valiente
F. Gimeno-Valiente
JMJ. Martín-Arana
J. Martín-Arana
RTR. Tébar-Martínez
R. Tébar-Martínez
VGV. Gambardella
V. Gambardella
CMC. Martínez-Ciarpaglini
C. Martínez-Ciarpaglini
NTNoelia Tarazona
Noelia Tarazona
In the setting of localized colon cancer (CC), circulating tumor DNA (ctDNA) monitoring in plasma has shown potential for detecting minimal residual disease (MRD) and predicting a higher risk of recurrence. With the tumor-only sequencing approach, however, germline variants may be misidentified as somatic variations, precluding the possibility of tracking in up to 11% of patients due to a lack of known somatic mutations. In this study, we assess the potential value of adding white blood cells (WBCs) to tumor tissue sequencing to enhance the accuracy of sequencing results. A total of 148 patients diagnosed with localized CC were prospectively recruited at the Hospital Clínico Universitario in Valencia (Spain). Employing a custom 29-gene panel, sequencing was conducted on tumor tissue, plasma and corresponding WBCs. Droplet digital PCR and amplicon-based NGS were performed on plasma samples post-surgery to track MRD. Oncogenic somatic variants were identified by annotating with COSMIC, OncoKB and an internal repository of pathogenic mutations database. A variant prioritization analysis, mainly characterized by the match of oncogenic mutations with the evidence levels defined in OncoKB, was carried out to select specific targeted therapies. Utilizing paired tumor and WBCs sequencing, we identified somatic mutations in all patients (100%) within our cohort, compared to 89% using only tumor tissue. Consequently, the top 10 most frequently mutated genes for plasma monitoring were altered. The sequencing of WBCs identified 9% of patients with pathogenic mutations in the germline, with APC and TP53 being the most frequently mutated genes. Additionally, mutations in genes related to clonal hematopoiesis of indeterminate potential were detected in 27% of the cohort, with TP53, KRAS, and KMT2C being the most frequently altered genes. There were no observed differences in the sensitivity of monitoring MRD using ddPCR or amplicon-based NGS (p = 1). Ultimately, 41% of the patients harbored potentially targetable alterations at diagnosis. The germline testing method not only enhanced sequencing results and raised the proportion of patients eligible for plasma monitoring, but also uncovered the existence of pathogenic germline variations, thereby aiding in the identification of patients at a higher risk of hereditary cancer syndromes.

21 November 2022 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
Federica PapaccioFederica Papaccio
Federica Papaccio
MCManuel Cabeza-Segura
Manuel Cabeza-Segura
BGBlanca Garcia-Micò
Blanca Garcia-Micò
NTNoelia Tarazona
Noelia Tarazona
DRDesamparados Roda
Desamparados Roda
Andres CervantesAndres Cervantes
Andres Cervantes
Precision medicine approaches for solid tumors are mainly based on genomics. Its employment in clinical trials has led to somewhat underwhelming results, except for single responses. Moreover, several factors can influence the response, such as gene and protein expression, the coexistence of different genomic alterations or post-transcriptional/translational modifications, the impact of tumor microenvironment, etc., therefore making it insufficient to employ a genomics-only approach to predict response. Recently, the implementation of patient-derived organoids has shed light on the possibility to use them to predict patient response to drug treatment. This could offer for the first time the possibility to move precision medicine to a functional environment.

17 November 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
GBGema Bruixola
Gema Bruixola
JMJorge Martín-Arana
Jorge Martín-Arana
FGFrancisco Gimeno-Valiente
Francisco Gimeno-Valiente
FVFranz Villarroel-Espíndola
Franz Villarroel-Espíndola
CAClara Alfaro-Cervelló
Clara Alfaro-Cervelló
NTNoelia Tarazona
Noelia Tarazona
Background: Accurate post-treatment assessment after definitive chemoradiotherapy (CRT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) remains challenging due to limitations of standard imaging. We evaluated the diagnostic performance, prognostic value and optimal timing of circulating tumor DNA (ctDNA) for molecular residual disease (MRD) detection. Methods: Seventy-four patients with LA-HNSCC treated with definitive CRT were prospectively enrolled. Plasma samples were collected before treatment, at 8 and 12 weeks after CRT, and during follow-up. ctDNA was analysed using a plasma-only methylation-based assay. Diagnostic performance for recurrence detection and associations with progression-free survival (PFS) and overall survival (OS) were evaluated and compared with 12-week PET/CT findings. Results: Baseline ctDNA was detectable in 85.1% of patients. Among post-treatment timepoints, week-12 ctDNA showed the highest diagnostic accuracy for recurrence detection, with 69% sensitivity, 100% specificity, 100% positive predictive value, and 76% negative predictive value. Detectable week-12 ctDNA was associated with shorter PFS (HR, 6.44; 95% CI, 2.73–16.74; p<0.001) and OS (HR, 7.31; 95% CI, 2.80–22.31; p<0.001 ). Longitudinal ctDNA surveillance identified additional recurrences among patients with initially undetectable week-12 ctDNA. Exploratory analyses integrating PET/CT and ctDNA identified prognostically distinct PFS groups (log-rank P=0.033), with the greatest additional prognostic stratification observed among PET partial-responders. Conclusions: Plasma-only methylation-based ctDNA provided high-specificity prognostic information after definitive CRT in LA-HNSCC, particularly at week 12 and in PET partial-responders. ctDNA may complement PET/CT for post-treatment risk stratification, but should not be used as a stand-alone test to exclude recurrence.